Vulvar Cancer Treatment in India
Expert vulvar cancer treatment in India — wide local excision, sentinel lymph node biopsy, and radiation therapy. Gynecologic oncologists prioritize function and quality of life.
Estimated cost: $3,500 – $7,000 · Average stay: 5–8 days
Vulvar cancer is the fourth most common gynecologic cancer, accounting for approximately 50,000 new cases globally each year. The disease predominantly affects older women, with a median age at diagnosis of 65–70 years. However, a younger age cohort driven by HPV infection — particularly HPV-16 — has emerged in recent decades. Two major etiologic pathways exist: HPV-related vulvar SCC (warty/basaloid type, affecting younger women) and HPV-independent vulvar SCC (keratinizing type, arising in a background of lichen sclerosus, affecting older women).
Modern treatment of vulvar cancer has been transformed by the recognition that the historically aggressive approach — radical vulvectomy (removal of the entire external genitalia) — is unnecessary for most early-stage tumors and associated with significant physical, sexual, and psychosocial morbidity. Individualized, function-preserving surgery — wide local excision with adequate margins — achieves equivalent oncologic cure rates for stage I–II tumors with dramatically better quality-of-life outcomes.
The management of inguinofemoral lymph nodes — which are the primary site of regional spread — has similarly evolved from routine radical lymphadenectomy to sentinel lymph node biopsy in clinically node-negative patients. SLNB dramatically reduces the morbidity of treatment (lymphedema, wound breakdown) while maintaining equivalent staging accuracy and cancer control.
India's gynecologic oncology centers offer comprehensive vulvar cancer care combining expert surgery with appropriate adjuvant radiation therapy.
Types and Stages of Vulvar Cancer
Vulvar squamous cell carcinoma (SCC) accounts for approximately 90% of vulvar cancers. Melanoma, Bartholin gland carcinoma, and Paget's disease are less common.
FIGO staging:
- Stage IA: Single lesion ≤2 cm, invasion ≤1 mm, no nodal involvement. Excision curative; no lymph node surgery required. 5-year survival: 95%+.
- Stage IB: Lesion >2 cm or >1 mm invasion, no nodal involvement. Wide local excision + SLNB. 5-year survival: 80–90%.
- Stage II: Any tumor size with adjacent spread (lower vagina, urethra, or anus) but no nodal involvement. 5-year survival: 65–80%.
- Stage IIIA: 1–2 lymph nodes with micrometastases or macrometastasis ≤5 mm. 5-year survival: 55–70%.
- Stage IIIB–C: 2+ involved nodes or extracapsular spread. Adjuvant radiation essential. 5-year survival: 25–45%.
- Stage IVA: Adjacent organ invasion or fixed/ulcerated nodes. Multimodal treatment. 5-year survival: 15–30%.
Who Is a Candidate for Vulvar Cancer Treatment?
Surgical candidates: all patients with stage I–III vulvar cancer who are medically fit. Wide local excision with adequate surgical margins (≥8 mm histologically, correlating with ≥1 cm gross margins) is the standard surgery for most primary vulvar tumors. The goal is complete tumor removal without unnecessarily mutilating surgery.
Sentinel lymph node biopsy candidates: all patients with stage IB and above, clinically N0 (no palpable enlarged groin nodes), and tumors not involving the midline (clitoris, perineum) where bilateral SLNB is required. SLNB with technetium-99m and blue dye identifies the sentinel nodes with 95% sensitivity. Node-negative patients avoid complete inguinal lymphadenectomy and its morbidity.
Radiation therapy candidates: patients with positive inguinal lymph nodes (N+) require adjuvant radiation to the groin and pelvis after surgery to reduce regional recurrence risk by 50%. Concurrent cisplatin chemosensitization is used in high-risk cases.
Primary chemoradiation candidates: patients with locally advanced (stage IIIB–IVA) disease involving the urethra, vagina, rectum, or fixed groin nodes who would require exenterative surgery (removal of the bladder or rectum) for resection. Concurrent cisplatin + radiation can downstage these patients and allow subsequent less morbid surgery.
Vulvar Cancer Surgery and Adjuvant Treatment
Wide local excision (WLE) removes the primary vulvar tumor with a minimum 1 cm gross margin on all sides, excising down to the inferior fascia of the urogenital diaphragm. Closure is achieved by primary suture whenever possible; skin-sparing flap reconstruction is used for larger defects.
The critical surgical principle in vulvar cancer is that two separate incisions are used for the primary tumor and the inguinal lymph node dissection, rather than the en-bloc radical vulvectomy that was standard for decades. The "triple incision technique" dramatically reduces wound breakdown and disfigurement while achieving equivalent oncologic results.
Sentinel lymph node biopsy: technetium-99m nanocolloid (and blue dye) is injected peritumorally and allowed to drain. The sentinel nodes are identified by a gamma probe and/or blue dye staining in the groin and excised. If sentinel nodes contain metastatic disease on frozen section or final pathology (confirmed on ultrastaging), complete inguinofemoral lymphadenectomy is performed.
Adjuvant radiation: inguinal and pelvic radiation (45–50 Gy) is delivered to patients with 2+ positive nodes, extracapsular extension, or one node with macrometastasis. Concurrent cisplatin improves local control.
Procedure Steps
- Colposcopy and biopsy with full pathological assessment including depth of invasion and grade.
- Staging MRI vulva and pelvis for tumor extent; CT abdomen/pelvis for lymph node assessment.
- Multidisciplinary gynecologic oncology team review.
- Wide local excision with intraoperative margin assessment by frozen section.
- Sentinel lymph node biopsy (bilateral if midline tumor) under gamma probe and blue dye guidance.
- Complete inguinofemoral lymphadenectomy if sentinel node positive.
- Wound closure or flap reconstruction for large defects.
- Adjuvant inguinal + pelvic radiation ± cisplatin for lymph node positive disease.
Vulvar Cancer Treatment Approaches
Wide Local Excision
Surgical removal of the vulvar tumor with minimum 1 cm margins while preserving as much normal vulvar tissue as possible. Equivalent oncologic outcomes to radical vulvectomy for stage I–II disease with dramatically better functional and quality-of-life outcomes.
Cost: $3,500 – $7,000
Sentinel Lymph Node Biopsy
Minimally invasive lymph node staging identifying the first draining inguinal nodes. Avoids complete inguinal lymphadenectomy (and its significant lymphedema risk) in the majority of stage I–II patients who are node-negative. The standard lymph node assessment for eligible vulvar cancer patients.
Cost: $2,000 – $4,000 (bilateral)
Adjuvant Inguinal + Pelvic Radiation
External beam radiation (45–50 Gy) to the bilateral groins and lower pelvis after surgery for node-positive vulvar cancer. Reduces groin and pelvic recurrence risk by approximately 50% compared to surgery alone. Required for most N+ patients to achieve acceptable regional control.
Cost: $3,000 – $6,000 (full course)
Primary Chemoradiation (Locally Advanced)
Concurrent cisplatin chemosensitization with radiation for locally advanced vulvar cancer requiring exenterative surgery. Achieves significant tumor regression allowing less morbid surgery in a meaningful proportion of patients. Cisplatin 40 mg/m² weekly + radiation 45–60 Gy.
Cost: $4,000 – $8,000
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $3,500 – $7,000 — Save 65–75%
UAE — $6,000 – $11,000 — Save 50–60%
USA / UK — $15,000 – $35,000+ — Baseline
Vulvar cancer treatment in India is 65–75% less expensive than in the USA, with equivalent gynecologic oncology expertise at JCI-accredited hospitals. India's gynecologic oncologists are trained in sentinel lymph node techniques and organ-preserving surgery that maximizes patients' quality of life alongside cure rates.
Recovery & Follow-up
Hospital stay after wide local excision ± sentinel node biopsy is typically 3–5 days. Full wound healing takes 3–6 weeks, particularly for larger excisions. Groin wound breakdown is the most common complication, managed with local wound care. Adjuvant radiation starts 4–6 weeks after surgery. Long-term management focuses on lymphedema prevention (compression stockings after groin dissection) and vaginal/vulvar dryness management.
Recovery Tips
- Meticulous wound hygiene is essential in the vulvar area during recovery — sitz baths twice daily.
- Compression stockings must be worn immediately after inguinal lymphadenectomy to prevent lymphedema.
- Report any groin wound breakdown or swelling promptly — early management prevents progression.
- Pelvic floor physiotherapy helps with sexual rehabilitation after vulvar cancer surgery.
- Report any new vulvar lesion, skin change, or groin lump at any follow-up — vulvar cancer has a 30% risk of local recurrence.
Risks & Complications
Wide local excision risks include wound dehiscence, infection, and local recurrence (5–15%). Sentinel node biopsy risks include false-negative results (3–5%), lymphedema if sentinel node is false-negative and subsequent groin recurrence occurs. Inguinal lymphadenectomy carries 30–50% risk of lower limb lymphedema. Radiation risks include acute perineal skin reaction, bowel changes, and long-term vaginal dryness/stenosis.
Why GAF Healthcare
Gaf Healthcare connects vulvar cancer patients with India's specialized gynecologic oncology programs, where experienced surgeons perform organ-preserving surgery and sentinel node biopsy techniques that maximize quality of life. We coordinate the complete multidisciplinary care pathway from diagnosis to adjuvant radiation and long-term surveillance.
Frequently Asked Questions
What is the cure rate for early-stage vulvar cancer?
Stage I vulvar cancer: 5-year survival of 85–95% with wide local excision ± sentinel node biopsy. Stage II: 65–80%. These excellent outcomes are achievable without radical vulvectomy — the disfiguring operation that was once standard. The key is receiving treatment from an experienced gynecologic oncologist.
What is sentinel lymph node biopsy and do I need it?
SLNB identifies the first inguinal lymph nodes draining the vulvar tumor. It is recommended for all stage IB and above tumors with clinically uninvolved lymph nodes. If the sentinel nodes are negative (no cancer), the remaining inguinal nodes are almost certainly clear — avoiding a full dissection with its 30–50% lymphedema risk.
Will I need radiation after surgery for vulvar cancer?
Adjuvant radiation is recommended for node-positive vulvar cancer — generally when 2+ inguinal nodes are involved, or when extracapsular spread is present. It is not routinely given for node-negative disease. The decision is made by the gynecologic oncology team based on final pathology.
Is vulvar cancer related to HPV?
Approximately 40–50% of vulvar SCCs are HPV-related (predominantly HPV-16), arising as warty or basaloid SCC, more common in younger women. The remaining 50–60% are HPV-independent, arising in older women on a background of lichen sclerosus, and tend to be keratinizing SCC. HPV vaccination in young women reduces the risk of HPV-related vulvar cancer.
What are the side effects of vulvar cancer treatment?
Surgery side effects include wound breakdown (most common), infection, and leg swelling if lymphadenectomy is performed. Long-term effects include sexual dysfunction (vaginal dryness, pain, changed sensation), urinary changes, and lymphedema. Radiation causes acute perineal skin reaction and long-term vaginal dryness/stenosis. A pelvic floor physiotherapist and gynecologic rehabilitation team significantly improve long-term outcomes.